Study wrapper · #1319
Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.
Editor's note
The underlying trials were randomised, double-blind and 52 weeks long, which gives these subgroup readings a solid foundation, and the consistency across five different baseline splits is the substantive finding. The authors label the work descriptive and hypothesis-generating for good reason: post hoc subgroup analyses are not powered for the comparisons they make and cannot support claims about who responds best. The author list includes Eli Lilly affiliations, consistent with sponsor-conducted analysis of the SURMOUNT-OSA program (NCT05412004).
Plain-language abstract
These post hoc analyses of the two phase 3 SURMOUNT-OSA trials asked whether tirzepatide's effect on obstructive sleep apnoea varied by patient starting characteristics. Across subgroups defined by age, sex, body mass index, baseline apnoea severity and neck circumference, participants on tirzepatide showed larger reductions in apnoea-hypopnoea index than placebo, ranging from about 12 to 52 fewer events per hour. Body weight, systolic blood pressure and hypoxic burden also improved across subgroups. Between 68 and 79 percent of tirzepatide participants moved to a less severe apnoea category, while most placebo participants stayed where they started.